Key result
Revascularization for stable coronary artery disease was associated with higher 1-year health care costs than medical management (mean $27,786 vs $18,069; PCI cost ratio 1.27, CABG cost ratio 2.62).
Why the study?
Does revascularization increase 1-year health care costs compared to medical treatment in patients with stable coronary artery disease?
Cohort (n=39,126)
Yes
Does revascularization increase 1-year health care costs compared to medical treatment in patients with stable coronary artery disease?
Effect estimate: cost ratio 1.27 for PCI, 2.62 for CABG (95% CI 1.24-1.31 for PCI, 2.53-2.71 for CABG)
Absolute Event Rate: 27786% vs 18069%
In patients with stable coronary artery disease, initial treatment with revascularization (PCI or CABG) is associated with significantly higher 1-year health care costs compared to medical therapy.
Higher costs with revascularization support prioritizing medical therapy where appropriate; leaves open causal effects and cost-effectiveness in randomized settings.
BACKGROUND: Cardiovascular disease is costly, and annual expenditures are projected to increase. Our objective was to examine the variation in patient-level costs and identify drivers of cost in patients with stable coronary artery disease. METHODS: In this retrospective cohort study using administrative databases in Ontario, Canada, we identified all patients with stable coronary artery disease after index angiography between Oct. 1, 2008, and Sept. 30, 2011. We excluded patients with a myocardial infarction within 90 days before the index, with normal coronaries, or with mild coronary disease. We categorized hospitals into low, medium or high revascularization ratio centres. The primary outcome was cumulative 1-year health care costs. A hierarchical generalized linear model identified patient, physician and hospital characteristics associated with patient costs, with 2 main covariates of interest: treatment allocation (medical v. percutaneous coronary intervention v. coronary artery bypass grafting) and hospital revascularization ratio. RESULTS: A total of 183 630 angiography procedures were performed in Ontario during the study period. The final cohort included 39 126 patients with stable coronary artery disease, of which 15 138 received medical treatment and 23 988 received revascularization. The mean 1-year cost was $24 026 (interquartile range $8235-$30 511). The mean costs for medical management and revascularization were $18 069 and $27 786, respectively. The strongest predictor of costs was revascularization (percutaneous coronary intervention: cost ratio 1.27, 95% CI [confidence interval] 1.24-1.31; coronary artery bypass grafting: cost ratio 2.62, 95% CI 2.53-2.71). Hospital revascularization ratio did not significantly affect costs. There was no significant interaction between treatment and revascularization ratio. INTERPRETATION: Most health care costs were due to acute care hospital admissions, and costs were higher for patients undergoing revascularization than medical therapy. This study suggests that treatment decision has a substantial impact on health care resources.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2016) conducted a cohort in stable coronary artery disease (n=39,126). Revascularization vs. Medical management was evaluated on cumulative 1-year health care costs (cost ratio 1.27 for PCI, 2.62 for CABG, 95% CI 1.24-1.31 for PCI, 2.53-2.71 for CABG). Revascularization for stable coronary artery disease was associated with higher 1-year health care costs than medical management (mean $27,786 vs $18,069; PCI cost ratio 1.27, CABG cost ratio 2.62).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: